On July 14, 2022, the Food and Drug Administration approved crizotinib (Xalkori, Pfizer Inc.) for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT).
Read MoreIn February 2022, President Biden announced and laid out an ambitious agenda to boost and speed up the fight against cancer, including a national year of action on cancer screening and a new Cancer Cabinet to drive progress government-wide. President Biden announced a revival of his audacious 2016 initiative - Cancer Moonshot - that is designed to dramatically accelerate progress against cancer.
Read More
